Caterpillar bids for Australia’s RPMGlobal- AFR
David Altshuler, the Executive Vice President and Chief Scientific Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a prominent $123 billion biotechnology company with strong financial health according to InvestingPro, has recently sold shares of the company. According to a recent SEC filing, Altshuler sold 848 shares of common stock on February 25, 2025, at a price of $480.95 per share, totaling approximately $407,845. This transaction was executed as part of a pre-established trading plan under Rule 10b5-1, which Altshuler entered into on August 8, 2024.
Additionally, on February 24, Altshuler disposed of 3,971 shares at a price of $483.28 per share, as part of a separate transaction. Following these transactions, Altshuler holds 40,200 shares of Vertex Pharmaceuticals.
In other recent news, Vertex Pharmaceuticals Incorporated has been the focus of several analyst updates and strategic developments. TD Cowen reaffirmed its Buy rating with a $525 price target, highlighting Vertex as its top large-cap biotech pick for 2025. This endorsement follows a strong fourth-quarter performance where cystic fibrosis revenues reached $2.9 billion, surpassing the consensus estimate. Vertex’s full-year 2025 revenue guidance is set between $11.75 billion and $12 billion, indicating an 8% year-over-year growth at the midpoint. Truist Securities also raised its price target to $520, maintaining a Buy rating, driven by positive feedback on the launches of Vertex’s drugs Alyftrek and Journavx.
Meanwhile, RBC Capital Markets adjusted its price target slightly to $408, maintaining a Sector Perform rating, amid enthusiasm for Journavx as a non-opioid pain treatment. BMO Capital Markets kept its Outperform rating with a $545 target, recognizing Vertex’s growth potential and portfolio diversification through 2025. The company’s strategy includes the launch of Alyftrek and Journavx, with expectations for rapid market penetration and strong volume growth, respectively. Additionally, DA Davidson maintained its Buy rating with a $62 target, expressing confidence in Vertex’s resilience against industry challenges. These updates reflect a generally optimistic outlook for Vertex’s financial performance and strategic positioning in the pharmaceutical industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.